SynthesisInternational urology and nephrology2023
Microwave ablation versus radiofrequency ablation for patients with primary and secondary hyperparathyroidism: a meta-analysis.
Synthesis in International urology and nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 3 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Timing of parathyroidectomy in kidney transplant candidates: a systematic review and a proposed clinical algorithm.Frontiers in endocrinology · 2026Pooled it
- Percutaneous microwave ablation of hyperfunctioning parathyroid lesions under multiparametric ultrasound guidance for primary hyperparathyroidism: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Efficacy and safety of radiofrequency ablation for hyperparathyroidism: a meta-analysis and systematic review.European radiology · 2025Pooled it
- Radiofrequency ablation as an alternative treatment for hyperparathyroidism: a case study of a single parathyroid adenoma and review of the literature.Hormones (Athens, Greece) · 2026Review
- Thermal ablation for primary hyperparathyroidism: long-term follow-up results.European radiology · 2026Article
- Interventional Radiology in the Management of Parathyroid Disorders: Current Diagnostic and Therapeutic Approaches.Journal of clinical medicine · 2026Review
- Ultrasound-guided microwave ablation for primary hyperparathyroidism in a pregnancy patient with medullary sponge kidney: a case description and literature analysis.Quantitative imaging in medicine and surgery · 2026Article
- Evaluation of Radiofrequency Ablation Safety and Efficacy in Primary Hyperparathyroidism: A Single-Center Retrospective Study in Taiwan and Literature Review.The Kaohsiung journal of medical sciences · 2025Review
- Secondary hyperparathyroidism in chronic kidney disease: A narrative review focus on therapeutic strategy.Clinical medicine (London, England) · 2024Review
- Complications after radiofrequency ablation of hyperparathyroidism secondary to chronic kidney disease.Renal failure · 2023Article
- Advancements in Microwave Ablation Techniques for Managing Pancreatic Lesions.Life (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveThermal ablation, including microwave ablation (MWA) and radiofrequency ablation (RFA), has been recommended for the treatment of primary hyperparathyroidism (PHPT) and refractory secondary hyperparathyroidism (SHPT). This meta-analysis was conducted to evaluate the efficacy and safety of MWA and RFA in patients with PHPT and refractory SHPT.
methodsDatabases including PubMed, EMbase, the Cochrane Library, CNKI (China National Knowledge Infrastructure), and Wanfang were searched from inception to December 5, 2022. Eligible studies comparing MWA and RFA for PHPT and refractory SHPT were included. Data were analyzed using Review Manager software, version 5.3.
resultsFive studies were included in the meta-analysis. Two were retrospective cohort studies, and three were RCTs. Overall, 294 patients were included in the MWA group, and 194 patients were included in the RFA group. Compared with RFA for refractory SHPT, MWA had a shorter operation time for a single lesion (P < 0.01) and a higher complete ablation rate for a single lesion ≥ 15 mm (P < 0.01) but did not show a difference in the complete ablation rate for a single lesion < 15 mm (P > 0.05). There were no significant differences between MWA and RFA for refractory SHPT concerning parathyroid hormone (P > 0.05), calcium (P > 0.05), and phosphorus levels (P > 0.05) within 12 months after ablation, except that calcium (P < 0.01) and phosphorus levels (P = 0.02) in the RFA group were lower than those in the MWA group at one month after ablation. There was no significant difference between MWA and RFA concerning the cure rate of PHPT (P > 0.05). There were no significant differences between MWA and RFA for PHPT and refractory SHPT concerning the complications of hoarseness (P > 0.05) and hypocalcaemia (P > 0.05).
conclusionMWA had a shorter operation time for single lesions and a higher complete ablation rate for large lesions in patients with refractory SHPT. However, there was no significant difference in efficacy and safety between MWA and RFA in cases of both PHPT and refractory SHPT. Both MWA and RFA are effective treatment methods for PHPT and refractory SHPT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.